Our depletion experiments make unlikely the possible contribution of HRI in the residual phosphorylation of eIF2α and associated SGs formation that are both detected in PERK-depleted HCC, upon sorafenib administration (Fig. S6). The gene discussed is EIF2A; the disease is hepatocellular carcinoma.